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Over the last decade, severe infections due to
Streptococcus pyogenes and its complications
have reemerged in several parts of the
world (1-3). S. pyogenes is uniformly susceptible
to penicillin, which remains the drug of choice for
treating infections by this organism. Erythromy-
cin and other macrolides have been recommended
as alternative treatment for patients allergic to
penicillin (2,4); however, resistance to erythro-
mycin and related drugs in S. pyogenes has
become widespread (5). Resistance to erythromy-
cin was first described in 1955 in the United
Kingdom (6) and, more recently, has been
reported in Japan (7), Finland (8), Taiwan (9),
Australia (10), the United States (11), Spain
(12,13), and Italy (14-16).
From 1991 to 1996 in Genoa, the percentage
of  S. pyogenes resistant or with intermediate
resistance to erythromycin increased from 0% to
50% (17). This abrupt increase in the rate of
erythromycin-resistant strains is of concern,
since erythromycin has been effective against
most S. pyogenes isolates.
We investigated the prevalence and distribu-
tion of macrolide resistance phenotypes among S.
pyogenes and carried out a clinical study in
patients with S. pyogenes pharyngitis to correlate
clinical and microbiologic outcomes with in vitro
susceptibility patterns.
The Study
Ten pediatricians in Genoa (population
700,000) participated in this study. Children
included in the study had to have two or more of
the following signs and symptoms: oropharyn-
geal erythema, fever and sore throat, tonsillar
exudate or cervical lymphadenitis, and straw-
berry tongue.
S. pyogenes was confirmed by culture of
throat swabs in agar blood; ß-hemolytic colonies
were identified as S. pyogenes by the bacitracin
disk (Difco Laboratories, Detroit, MI) and latex-
agglutination test (Streptex, Wellcome, U.K.).
Minimum inhibitory concentrations (MICs) for
penicillin, cefixime, ceftriaxone, chloramphenicol,
rifampin, tetracycline, trimethoprim/sulfamethox-
azole, and vancomycin were determined by using
the PASCO MIC gram-positive panel (Difco
Laboratories, Detroit, MI), supplemented with
horse blood. MICs for clindamycin, erythromycin,
azithromycin, and clarithromycin were deter-
mined by using E-test strips (AB Biodisk, Solna,
Sweden) on Mueller-Hinton agar supplemented
with 5% horse blood incubated in an atmosphere
containing 5% carbon dioxide. Phenotypes of
macrolide resistance were differentiated according
to the description of Seppala et al. (18) and
Suttcliffe et al. (19). Resistance to both
erythromycin and clindamycin indicated a
constitutive type of resistance (CR), blunting of
the clindamycin zone of inhibition proximal to
erythromycin indicated an inducible type of
resistance (IR), and susceptibility to clindamycin
without blunting indicated the M-phenotype of
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Table 1. In vitro susceptibilitya of Streptococcus pyogenes
from 180 pharyngitis patients
Erythromycin-
 resistant
Erythromycin   M-pheno-
susceptible   type IRb   CRc
Erythromycin 0.25 32 64 >128
Clarithromycin 0.5 16 64 >128
Azithromycin 0.25 16 64 >128
Clindamycin 0.5   1   1 >128
Rifampin 1   1   1       2
Chloramphenicol <4 <4 <4     <4
Ciprofloxacin 0.25   1   2       2
aMIC90 in  ￿g/ml; bIR = Inducible-type resistance; cCR =
Constitutive-type resistance.
Table 2. Frequency of clarithromycin failure, by
susceptibility profile
     No.     No.
 patients treatment
    treated failed  (%)     p value
Erythromycin- 25   3 (12)
 susceptible
Erythromycin- 19   7 (36.8) 0.07a
 resistant
   CRb   6   6 (100) 0.0001a
   other phenotypes 13     1  (7.6) 1.0a; 0.0002c
Total 44 10  (22.7)
aFor comparison of percentage of failure with erythromycin-
susceptible;  bCR = Constitutive-type resistance;cFor com-
parison of percentage of failure between CR and other
phenotypes of resistance.
resistance. For all antibiotics tested, the break-
points suggested by the National Committee for
Clinical Laboratory Standards were used (20,21).
At their physicians’ discretion, eligible
patients received a 10-day course of one of the
following drugs: amoxicillin 75 mg/kg three times
a day; amoxicillin/clavulanic acid 50 mg/kg twice
a day; cefaclor 50 mg/kg twice a day; or
clarithromycin 15 mg/kg twice a day. The
attending physician was blinded to the results of
microbiologic tests. Fisher’s exact test and the
chi-square test were performed by using Epi Info,
version 6. For all tests, a p value of < 0.05 was
considered statistically significant.
Six hundred children ages 1-13 years (median
age 7.0) with acute pharyngitis were observed,
and 180 (30%) whose throat cultures were
positive for S. pyogenes were included in the
study. Amoxicillin was prescribed to 42 patients,
amoxicillin/clavulanic acid to 56, cefaclor to 35,
and clarithromycin to 44. The clinical cure rates
were 79.5% (35 of 44) in the clarithromycin group,
92% (39 of 42) in the amoxicillin group (p = 0.14
for comparison with clarithromycin), 100% (56 of
56) in the amoxicillin/clavulanic acid group (p =
0.0003 for comparison with clarithromycin), and
97.1% (34 of 35) in the cefaclor group (p = 0.03 for
comparison with clarithromycin).
Results of post-treatment throat swabs were
available from 159 patients. Bacterial eradication
response rates were 77.2% (34 of 44) with
clarithromycin, 88.8% (32 of 36) with amoxicillin
group (p = 0.28 for comparison with clarithromy-
cin), 95.8% (46 of 48) with amoxicillin/clavulanic
acid (p = 0.03 for comparison with clarithromy-
cin), and 90.3% (28 of 31) with cefaclor (p = 0.24
for comparison with clarithromycin). All 180 strains
were susceptible to penicillin (MIC90  <0.06 ￿g/l) and
other ß-lactams tested (Table 1). Overall, 69
(38.3%) of the 180 isolates were resistant to one or
more macrolides, 7 (3.9%) to clindamycin, and 21
(11.6%) to the 16-member macrolide rokitamycin.
Sixty-two percent (43 of 69 strains) of the
erythromycin-resistant strains showed the M
phenotype of resistance, 11.5% (8 strains) the CR
phenotype, and 26.0% (18 strains) the IR
phenotype.
Among the 159 patients, 19 (43.1%) of 44
treated with clarithromycin, 16 (44.4%) of 36
treated with amoxicillin, 13 (27.0%) of 48 treated
with amoxicillin/clavulanic acid, and 8 (25.8%) of
31 treated with cefaclor had S. pyogenes resistant
to erythromycin at the first swab collected before
treatment.
S. pyogenes was eradicated in 12 (63.1%) of
the 19 patients with erythromycin-resistant
isolates and in 22 (88.0%) of 25 patients with
erythromycin-susceptible isolates treated with
clarithromycin (p = 0.07). As a control, the results
of ß-lactam treatment were also studied. The
rates of microbiologic eradication in patients with
erythromycin-resistant isolates were 87.5% (14 of
16) for amoxicillin, 100% (13 of 13) for
amoxicillin/clavulanic acid, and 100% (8 of 8) for
cefaclor. Rates of microbiologic eradication for
erythromycin-susceptible strains were 90% (18 of
20) for amoxicillin, 94.2% (33 of 35) for
amoxicillin/clavulanic acid, and 86.9% (20 of 23)
for cefaclor (p = 1.0; p = 1.0; p = 0.54, respectively,
for comparison with erythromycin-resistant
isolates).
In clarithromycin-treated patients, 6 of the 7
treatment failures were related to isolates with a
CR phenotype (p = 0.0002 for comparison of
percentages with other phenotypes of resistance,
and p = 0.0001 for comparison with erythromycin-
susceptible isolates) (Table 2).Dispatches
182 Emerging Infectious Diseases Vol. 6, No. 2, March–April 2000
Conclusions
Our results show that in Genoa, 38% of
S. pyogenes isolated from pharyngitis patients
are erythromycin resistant. Sixty-three percent
of such isolates belonged to a recently reported,
noninducible M phenotype, described as having
low-level resistance to erythromycin and sensitiv-
ity to clindamycin and 16-member macrolides
(18). Twenty-six percent of resistant strains were
classified as IR phenotype, characterized by low-
level resistance to erythromycin and inducible
resistance to 16-member macrolides and
clindamycin after exposure to subinhibitory
concentrations of erythromycin (5). The remaining
isolates (11.5%) showed the CR phenotype,
characterized by high-level resistance to
macrolides and clindamycin.
Our study also examined whether in-vitro
resistance could be a good predictor of clinical
outcome in children with pharyngitis. Although
physicians were instructed to choose the
antibiotic without regard to clinical signs and
symptoms, a bias due to selective antibiotic choice
based on clinical presentation cannot be excluded.
Clarithromycin was prescribed to 44 patients, 19
with erythromycin-resistant isolates and 25 with
erythromycin-susceptible isolates. Although the
rate of microbiologic eradication did not differ
between patients with erythromycin-resistant
isolates and those with erythromycin-susceptible
isolates (63.1% vs. 88.0%; p = 0.07), a clear trend
was observed toward a higher rate of eradication
among erythromycin-susceptible isolates.
When results in clarithromycin-treated
patients were analyzed by phenotype of
resistance, the rate of treatment failure was
100% (6 patients) for CR phenotype, compared
with 7.6% (1 of 13 patients) for other phenotypes
(p = 0.0002) and 12% (3 of 25 patients) for
erythromycin-susceptible isolates (p = 0.0001).
Failure of erythromycin to eradicate group A
streptococci with high levels of resistance to
erythromycin and lyncosamide has been reported
(22,23). Seppala et al. (8), in a retrospective
analysis of medical records, found that erythro-
mycin failed in 47% of pharyngitis patients with
erythromycin-resistant isolates, a rate signifi-
cantly higher than the 4% observed in patients
with erythromycin-susceptible isolates. The
susceptibility profile of these strains, however,
was consistent with phenotypes other than CR.
The eradication rate in patients with isolates
belonging to phenotypes other than CR, thus
showing low levels of resistance to macrolides,
was comparable with that observed for erythro-
mycin-susceptible isolates. However, our find-
ings suggest that CR phenotype will be an
accurate predictor of in-vivo failure of macrolides
in the treatment of streptococcal pharyngitis.
Whether the discrepancy between our results and
those of a previous Finnish study (8) should be
attributed to differing macrolides remains to be
proven by large, well-controlled studies. Despite
in-vitro cross-resistance with other 14-member
macrolides, clarithromycin is characterized by
elevated concentrations attained in different
tissues (including tonsil tissue) because of its
improved pharmacokinetic profile (5,24).
Because only a few alternative antimicrobial
agents can be used to treat pharyngitis in
patients allergic to ß-lactams, adequate interven-
tions include a controlled use of macrolides and
surveillance for the susceptibility of group A
streptococci. Determining erythromycin resis-
tance phenotypes seems to be a useful tool,
particularly in areas where macrolides are
frequently prescribed. Should the CR phenotype,
reported infrequently at present, become preva-
lent, its high-level resistance may threaten the
efficacy of macrolides and clindamycin in the
treatment of streptococcal pharyngitis.
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